Christopher McCanless, MD
Hematology & Oncology · Baton Rouge, LANPI 1013995646
Payments from drug & device makers
Across 937 payments — averaging $85.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$48K
- AstraZeneca$14K
- Merck$1K
- Novartis$1K
- Johnson & Johnson$898
- E.r. Squibb & Sons, L.L.C.$830
- plus $13K from 54 others
Across 2 payments — averaging $1905.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4K
What the payments were for
- Food & beverage$17,37595%
- Education$9955%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,873 in reported general payments places this provider in the 75th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 49 | $850,898 |
| PomalystPomalidomide | 36 | $812,379 |
| CalquenceAcalabrutinib Maleate | 32 | $480,722 |
| JakafiRuxolitinib Phosphate | 30 | $444,629 |
| KisqaliRibociclib Succinate | 19 | $333,221 |
| OnuregAzacitidine | 11 | $279,824 |
| XtandiEnzalutamide | 20 | $272,032 |
| TruqapCapivasertib | 11 | $250,774 |
| PiqrayAlpelisib | 11 | $226,917 |
| BrukinsaZanubrutinib | 20 | $209,672 |
| LynparzaOlaparib | 11 | $186,304 |
| TavalisseFostamatinib Disodium | 11 | $132,246 |
| EliquisApixaban | 113 | $86,478 |
| PromactaEltrombopag Olamine | 12 | $85,774 |
| Abiraterone Acetate | 11 | $30,982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Onureg | $830 | $1,092,20247 claims |
| AstraZenecaCalquence, Truqap, Lynparza | $13,549 | $917,79954 claims |
| Bristol Myers SquibbRevlimid | $606 | $850,89849 claims |
| NovartisKisqali, Piqray, Promacta | $1,323 | $645,91342 claims |
| Incyte CorporationJakafi | $323 | $444,62930 claims |
| Astellas Pharma US IncXtandi | $468 | $272,03220 claims |
| Beigene USA, Inc.Brukinsa | $408 | $209,67220 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $84 | $132,24611 claims |
| PfizerEliquis | $744 | $86,478113 claims |
| Johnson & JohnsonXarelto | $898 | $17,44124 claims |
| AbbVieSynthroid | $296 | $47711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Baton Rouge
- Hana SafahBaton Rouge$3.8M
- Nakhle SabaBaton Rouge$2.4M
- Victor LinBaton Rouge$2.3M
- Marshall StaggBaton Rouge$1.6M
- William VarnadoBaton Rouge$648K
- Andrew DalovisioBaton Rouge$389K
- Sobia OzairBaton Rouge$378K
- Sanjay JunejaBaton Rouge$346K
- Derrick SpellBaton Rouge$128K
- Harry Sequeira GrossBaton Rouge$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.